000282295 001__ 282295
000282295 005__ 20251212103343.0
000282295 0247_ $$2doi$$a10.1136/jnnp-2025-336208
000282295 0247_ $$2pmid$$apmid:40537251
000282295 0247_ $$2ISSN$$a0022-3050
000282295 0247_ $$2ISSN$$a0266-8637
000282295 0247_ $$2ISSN$$a0368-329X
000282295 0247_ $$2ISSN$$a1468-330X
000282295 0247_ $$2ISSN$$a2753-0477
000282295 0247_ $$2ISSN$$a2753-0485
000282295 037__ $$aDZNE-2025-01265
000282295 041__ $$aEnglish
000282295 082__ $$a610
000282295 1001_ $$00000-0002-3977-6995$$aVerde, Federico$$b0
000282295 245__ $$aCSF levels of the somatodendritic protein MAP2 are increased in ALS and predict shorter survival.
000282295 260__ $$aLondon$$bBMJ Publishing Group$$c2025
000282295 3367_ $$2DRIVER$$aarticle
000282295 3367_ $$2DataCite$$aOutput Types/Journal article
000282295 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1765455387_17915
000282295 3367_ $$2BibTeX$$aARTICLE
000282295 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282295 3367_ $$00$$2EndNote$$aJournal Article
000282295 520__ $$aPrevious proteomic work has identified the somatodendritic protein MAP2 as a new candidate cerebrospinal fluid (CSF) biomarker for amyotrophic lateral sclerosis (ALS).We measured CSF levels of MAP2 and neurofilament light chain (NFL) in a retrospective cohort of 251 patients with ALS and 108 neurological controls (NCs).Patients with ALS had a higher median CSF MAP2 level compared with NCs, leading to an area under the curve (AUC) of 0.7080 (p<0.0001). They also had a higher median CSF NFL level (p<0.0001), resulting in an excellent diagnostic performance (AUC=0.9641; p<0.0001). Among patients with ALS, CSF MAP2 correlated with disease progression rate (DPR) (r=0.3099; p<0.0001) and was negatively associated with survival (HR=3.174). CSF NFL also correlated with DPR (r=0.4936; p<0.0001) and was negatively associated with survival (HR=2.759). The association of MAP2 with DPR was independent from NFL (p=0.0037). Stratifying patients based on median levels of both biomarkers resulted in significant differences in median survival times (low NFL/low MAP2, 66 months; high NFL/low MAP2 and vice versa, 35 months; high NFL/high MAP2, 26 months; p<0.0001). MAP2 was also associated with genetic status in patients with ALS, as patients with no mutations in C9ORF72 or in SOD1, as well as C9ORF72-positive ones, had higher median levels compared with NCs (p<0.0001), while patients with SOD1 mutations did not significantly differ from NCs (p>0.9999).Our study shows that the somatodendritic protein MAP2 is a promising candidate CSF biomarker for ALS.
000282295 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000282295 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282295 650_7 $$2Other$$aALS
000282295 650_7 $$2Other$$aCSF
000282295 650_7 $$2Other$$aMOTOR NEURON DISEASE
000282295 650_7 $$2NLM Chemicals$$aBiomarkers
000282295 650_7 $$2NLM Chemicals$$aNeurofilament Proteins
000282295 650_7 $$2NLM Chemicals$$aneurofilament protein L
000282295 650_7 $$2NLM Chemicals$$aMicrotubule-Associated Proteins
000282295 650_7 $$2NLM Chemicals$$aMAP2 protein, human
000282295 650_7 $$2NLM Chemicals$$aC9orf72 Protein
000282295 650_7 $$0EC 1.15.1.1$$2NLM Chemicals$$aSuperoxide Dismutase-1
000282295 650_7 $$2NLM Chemicals$$aC9orf72 protein, human
000282295 650_2 $$2MeSH$$aHumans
000282295 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: cerebrospinal fluid
000282295 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: mortality
000282295 650_2 $$2MeSH$$aAmyotrophic Lateral Sclerosis: genetics
000282295 650_2 $$2MeSH$$aMale
000282295 650_2 $$2MeSH$$aFemale
000282295 650_2 $$2MeSH$$aMiddle Aged
000282295 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000282295 650_2 $$2MeSH$$aNeurofilament Proteins: cerebrospinal fluid
000282295 650_2 $$2MeSH$$aAged
000282295 650_2 $$2MeSH$$aRetrospective Studies
000282295 650_2 $$2MeSH$$aMicrotubule-Associated Proteins: cerebrospinal fluid
000282295 650_2 $$2MeSH$$aDisease Progression
000282295 650_2 $$2MeSH$$aC9orf72 Protein: genetics
000282295 650_2 $$2MeSH$$aAdult
000282295 650_2 $$2MeSH$$aSuperoxide Dismutase-1: genetics
000282295 7001_ $$0P:(DE-HGF)0$$aVávra, Jakub$$b1$$eFirst author
000282295 7001_ $$0P:(DE-2719)9001951$$aDorst, J.$$b2$$udzne
000282295 7001_ $$aElmas, Zeynep$$b3
000282295 7001_ $$aWiesenfarth, Maximilian$$b4
000282295 7001_ $$aDe Gobbi, Anna$$b5
000282295 7001_ $$aRatti, Antonia$$b6
000282295 7001_ $$00000-0003-4398-2051$$aPoletti, Barbara$$b7
000282295 7001_ $$0P:(DE-2719)9002007$$aTumani, Hayrettin$$b8
000282295 7001_ $$0P:(DE-2719)9000455$$aWeishaupt, Jochen$$b9
000282295 7001_ $$00000-0002-7698-3854$$aSilani, Vincenzo$$b10
000282295 7001_ $$00000-0001-5963-7426$$aTicozzi, Nicola$$b11
000282295 7001_ $$00000-0003-4273-4267$$aOtto, Markus$$b12
000282295 7001_ $$0P:(DE-2719)2812633$$aLudolph, Albert C$$b13$$udzne
000282295 7001_ $$0P:(DE-2719)9001560$$aOeckl, Patrick$$b14$$eLast author
000282295 773__ $$0PERI:(DE-600)1480429-3$$a10.1136/jnnp-2025-336208$$gVol. 96, no. 12, p. jnnp-2025-336208 -$$n12$$p1132 - 1143$$tJournal of neurology, neurosurgery, and psychiatry$$v96$$x0022-3050$$y2025
000282295 8564_ $$uhttps://pub.dzne.de/record/282295/files/DZNE-2025-01265_Restricted.pdf
000282295 8564_ $$uhttps://pub.dzne.de/record/282295/files/DZNE-2025-01265_Restricted.pdf?subformat=pdfa$$xpdfa
000282295 909CO $$ooai:pub.dzne.de:282295$$pVDB
000282295 9101_ $$0I:(DE-588)1065079516$$6P:(DE-HGF)0$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000282295 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001951$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000282295 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002007$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000282295 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812633$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000282295 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001560$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b14$$kDZNE
000282295 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000282295 9141_ $$y2025
000282295 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-28$$wger
000282295 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL NEUROSUR PS : 2022$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000282295 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NEUROL NEUROSUR PS : 2022$$d2024-12-28
000282295 9201_ $$0I:(DE-2719)5000073$$kAG Öckl$$lTranslational Mass Spectrometry and Biomarker Research$$x0
000282295 9201_ $$0I:(DE-2719)5000077$$kClinical Study Center (Ulm)$$lClinical Study Center (Ulm)$$x1
000282295 980__ $$ajournal
000282295 980__ $$aVDB
000282295 980__ $$aI:(DE-2719)5000073
000282295 980__ $$aI:(DE-2719)5000077
000282295 980__ $$aUNRESTRICTED